This trial will test if a combination of CAR T-cell therapy, Mosunetuzumab, and Polatuzumab Vedotin can shrink tumors.
1 Primary · 7 Secondary · Reporting Duration: Up to 2 years
Experimental Treatment
40 Total Participants · 1 Treatment Group
Primary Treatment: CAR-T Cell Therapy · No Placebo Group · Phase 2
Age 18 - 80 · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: